Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
AbivaxAbivax(US:ABVX) Globenewswire·2026-03-23 20:05

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026Abivax appoi ...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates - Reportify